Barclays PLC Increases Stake in Xencor, Inc. (NASDAQ:XNCR)

Barclays PLC lifted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 100.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 155,568 shares of the biopharmaceutical company's stock after acquiring an additional 78,066 shares during the quarter. Barclays PLC owned 0.22% of Xencor worth $3,128,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of XNCR. Quarry LP purchased a new position in Xencor in the second quarter valued at about $36,000. KBC Group NV raised its holdings in shares of Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 1,213 shares during the period. SG Americas Securities LLC purchased a new position in Xencor in the second quarter valued at approximately $154,000. XTX Topco Ltd bought a new position in Xencor during the second quarter valued at $196,000. Finally, Rockefeller Capital Management L.P. purchased a new stake in Xencor in the third quarter worth $205,000.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on XNCR. Wedbush reaffirmed an "outperform" rating and set a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th. Wells Fargo & Company started coverage on shares of Xencor in a report on Thursday, December 12th. They set an "overweight" rating and a $37.00 price objective on the stock. Piper Sandler upgraded shares of Xencor from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. Royal Bank of Canada upped their price target on shares of Xencor from $31.00 to $34.00 and gave the company an "outperform" rating in a research note on Thursday, September 26th. Finally, BMO Capital Markets reiterated an "outperform" rating and issued a $34.00 price objective (up from $32.00) on shares of Xencor in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $36.56.

Insider Activity

In other Xencor news, VP John R. Desjarlais sold 68,684 shares of Xencor stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the sale, the vice president now owns 200,104 shares of the company's stock, valued at $4,698,441.92. The trade was a 25.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Alan Bruce Montgomery sold 13,301 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $27.03, for a total value of $359,526.03. Following the transaction, the director now owns 9,140 shares in the company, valued at $247,054.20. This trade represents a 59.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 136,050 shares of company stock worth $3,277,609. 5.23% of the stock is currently owned by insiders.

Xencor Price Performance

NASDAQ XNCR traded down $0.28 on Tuesday, hitting $24.29. The stock had a trading volume of 197,509 shares, compared to its average volume of 624,033. The firm has a 50-day moving average of $23.53 and a 200-day moving average of $20.69. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -7.59 and a beta of 0.69. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a 52-week low of $15.31 and a 52-week high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. During the same quarter last year, the business posted ($0.40) earnings per share. The firm's revenue was down 81.9% compared to the same quarter last year. Equities analysts expect that Xencor, Inc. will post -3.71 EPS for the current year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.